Low-Dose Naltrexone for Multiple Sclerosis: Evidence, Dosing, and Clinical Considerations

At a Glance

Low-dose naltrexone sits at an unusual intersection in neurology: a generic, inexpensive drug with a plausible mechanism, growing patient advocacy, and a clinical trial record that—while still modest—warrants serious clinical consideration for people with multiple sclerosis. This article examines what the evidence actually shows, how to select and dose patients, and how LDN fits alongside contemporary disease-modifying therapies.

Why Naltrexone at Low Doses Is Not the Same Drug

Standard naltrexone (50 mg) is an opioid antagonist approved for alcohol use disorder and opioid dependence. At that dose, it completely blocks mu-opioid receptors around the clock—useful for dependence, but not the mechanism relevant to MS.

LDN works differently because of receptor rebound kinetics. A dose of 1.5–4.5 mg taken at bedtime produces peak receptor blockade for approximately 4–6 hours (roughly 2 AM to 6 AM), coinciding with the natural nocturnal surge in endogenous opioid activity. When the drug clears and receptors become accessible again, a rebound upregulation occurs: the body synthesises more endogenous opioids—specifically opioid growth factor (OGF, met-enkephalin)—and their receptors (OGFr) become more numerous and sensitive.

This OGF–OGFr axis is the core pharmacological story in MS. In healthy CNS tissue, OGF acts as a tonic inhibitor of cell proliferation, with particular effects on regulatory T-cells, astrocytes, and oligodendrocyte precursors. In MS, OGF signalling is dysregulated, contributing to both inflammatory and neurodegenerative processes.

Microglial Modulation: The Second Mechanism

Independently of the OGF axis, LDN exerts anti-inflammatory effects through Toll-like receptor 4 (TLR4) antagonism on microglia. Microglia in MS lesions are chronically activated, releasing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that perpetuate demyelination and axonal loss. Naltrexone at low doses appears to attenuate this microglial activation without suppressing the adaptive immune response—a meaningful distinction from broad immunosuppressants.

What the Clinical Evidence Shows

Phase II RCT in Primary Progressive MS

The landmark trial was a randomised, double-blind, placebo-controlled pilot study by Cree et al. (2010) enrolling 80 patients with primary progressive MS (PPMS). Patients received LDN 4.5 mg or placebo nightly for 8 weeks. The primary endpoint—EDSS change—did not differ significantly, but several secondary outcomes favoured LDN:

• Mental health quality of life (SF-36 mental health composite): significant improvement in LDN group (p = 0.04)
• Self-reported pain: significant reduction (p = 0.04)
• Fatigue: non-significant trend favouring LDN

Adverse events were minimal and nearly identical between groups, establishing the safety profile that subsequent research has consistently confirmed.

Observational and Registry Data

The LDN Research Trust patient registry, encompassing thousands of self-reported MS users, consistently shows:

• 80–85% of respondents report improved energy and fatigue
• 60–70% report reduced spasticity
• 40–50% report cognitive clarity improvements
• Side-effect rate: vivid dreams (most common, usually resolves in 2–4 weeks), mild insomnia on initiation

A 2014 survey study by Younger et al. found that MS patients rating LDN on a 0–10 symptom scale reported mean improvements of 2–3 points for fatigue, pain, and spasticity after 3 months.

Mechanism-Focused Preclinical Work

Animal models of experimental autoimmune encephalomyelitis (EAE)—the standard MS rodent model—demonstrate that LDN:

• Reduces lesion burden and axonal injury markers
• Preserves myelin thickness
• Attenuates microglial TLR4/NF-κB signalling

While animal data does not translate directly, the mechanistic consistency with human clinical signals is encouraging.

Patient Selection for LDN in MS

Who Responds Best

Clinical experience and registry data suggest the strongest candidates are:

Relapsing-remitting MS (RRMS) patients who:

• Have breakthrough fatigue and cognitive symptoms not fully controlled by their DMT
• Cannot tolerate fatigue as a side effect from interferons or other agents
• Seek an affordable, low-risk adjunct

Progressive MS (PPMS/SPMS) patients who:

• Lack approved disease-modifying options (PPMS has limited choices: ocrelizumab only, with significant cost and infusion burden)
• Prioritise quality-of-life outcomes alongside slowing progression
• Have had adequate trials of conventional approaches

Early MS / CIS patients who are surveillance-only and want a low-risk neuroprotective intervention while monitoring.

Who Should Not Use LDN

• Patients on full-dose opioid analgesia (opioids will not work while LDN is present; dose timing cannot reliably separate the effects)
• Active opioid dependence or patients in opioid maintenance therapy with methadone or buprenorphine
• Pregnancy: insufficient safety data; avoid
• Patients scheduled for elective surgery requiring opioid anaesthesia should pause LDN 5–7 days beforehand

Dosing Protocol

Initiation

1. Start at 1.5 mg nightly at bedtime (10 PM to midnight) for the first two weeks
2. If well tolerated, increase to 3.0 mg nightly for two further weeks
3. Target dose: 4.5 mg nightly — the most studied and clinically used dose
4. Some patients, particularly those with higher opioid sensitivity, respond well at 3.0 mg and do not need to increase

Formulation

LDN is not commercially available at the required dose and must be obtained from a compounding pharmacy. Options include:

• Oral capsules (most common, most stable)
• Liquid formulations (useful for those titrating in small increments)
• Sublingual drops (faster onset; less evidence for MS specifically)

Avoid tablets split from 50 mg commercial naltrexone: inaccurate dosing and erratic absorption are documented problems that undermine both efficacy and safety monitoring.

Timing Note

Bedtime dosing is essential—not a minor detail. The transient receptor blockade must coincide with the nocturnal endogenous opioid surge (approximately midnight to 4 AM) to produce the rebound upregulation that drives the therapeutic effect. Patients who shift the dose to morning or midday report markedly reduced benefit.

Integration with Disease-Modifying Therapies

One of LDN’s practical advantages in MS is its benign drug-interaction profile:

The one drug class to avoid combining with LDN is any full mu-opioid agonist. Tramadol is a partial agonist and presents a grey area; if MS pain requires tramadol, discuss dose timing carefully with a pharmacist—separation of 8–10 hours may allow both, but evidence is anecdotal.

Monitoring and Expectations

Timeline

• Weeks 1–2 (initiation): vivid dreams most common side effect; usually resolves spontaneously. Some patients note light insomnia on the first few nights.
• Weeks 4–8: first meaningful change typically in fatigue and mood/mental clarity
• Months 3–6: spasticity and pain benefits, where present, become more apparent
• Beyond 6 months: a proportion of users report reduced relapse frequency (observational; not established in RCT)

What to Measure

Use standardised patient-reported outcome measures at baseline and every 3–6 months:

• MSIS-29 (MS Impact Scale, 29 items) — captures physical and psychological dimensions
• FSSS or FSS (Fatigue Severity Scale) — most responsive to LDN in practice
• Neuro-QoL Cognition — for cognitive complaints
• Pain VAS — 0–10 numerical rating

Objective MRI surveillance continues on the schedule dictated by the DMT protocol; LDN does not change imaging frequency recommendations.

Dose Adjustments

If a patient experiences persistent sleep disruption beyond 3–4 weeks at 4.5 mg, step back to 3.0 mg as a maintenance dose. Many patients remain on 3.0 mg without loss of benefit. A small subset responds better at lower doses (1.5–2.5 mg), which may reflect higher endogenous opioid tone.

Related Articles

• Low-Dose Naltrexone: Complete Clinical Guide — foundational mechanisms, indications, and compounding guidance
• LDN for Fibromyalgia — dosing nuances and the fibromyalgia evidence base
• LDN for IBD and Crohn’s Disease — mucosal immune mechanisms and paediatric data
• LDN for Long COVID — post-viral neuroinflammation and fatigue applications
• Vagus Nerve Stimulation for Neuroinflammation — complementary neuromodulatory approach in inflammatory CNS disease
• LDN for Parkinson’s Disease — TLR4 and microglial mechanisms in dopaminergic neurodegeneration, with full dosing protocol

References

1. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–150. doi:10.1002/ana.22006
2. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x
3. Rahn KA, McLaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period. Brain Res. 2011;1381:243–253. doi:10.1016/j.brainres.2011.01.036
4. Zagon IS, McLaughlin PJ. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol. 1997;10(5):1019–1026.
5. Liu WM, Scott KA, Dennis JL, Kaminska E, Pearce AJ, Bhatt M. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy. Int J Oncol. 2016;49(2):793–802. doi:10.3892/ijo.2016.3567
6. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086
7. Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13(1):e232502. doi:10.1136/bcr-2019-232502